Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Myriad Genetics, Inc. - Common Stock (NQ:MYGN)

7.310 +0.070 (+0.97%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Myriad Genetics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
1 Momentum Stock for Long-Term Investors and 2 Facing Challenges
The stocks featured in this article are seeing some big returns. Over the past month, they’ve outpaced the market due to some combination of positive news, upbeat results, or supportive macro... 
Via StockStory
3 Russell 2000 Stocks with Open Questions
The Russell 2000 (^RUT) is packed with potential breakout stocks, thanks to its focus on smaller companies with high growth potential. However, smaller size also means these businesses often lack the... 
Via StockStory
Topics Regulatory Compliance
Myriad Genetics Announces Precise MRD Clinical Data Published in The Lancet Oncology
From Myriad Genetics, Inc.
Via GlobeNewswire
Earnings Scheduled For August 5, 2025
 
Via Benzinga
Earnings Preview: Myriad Genetics
 
Via Benzinga
New Meta-Analysis Demonstrates that Access to the GeneSight Test Can Significantly Improve Response and Remission Rates for Patients with Depression
Results published in the Journal of Clinical Psychopharmacology 
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences
From Myriad Genetics, Inc.
Via GlobeNewswire
3 Stocks Under $10 We Approach with Caution
Stocks under $10 pique our interest because they have room to grow (as well as the most affordable option contract premiums). That doesn’t mean they’re bargains though, and we urge investors to be... 
Via StockStory
Opendoor, SmartRent, Myriad Genetics, Reddit, and Unity Stocks Trade Down, What You Need To Know
A number of stocks fell in the afternoon session after the major indices continued to pull back, with technology stocks accounting for most of the market's largest decliners. A key reason for this... 
Via StockStory
Topics Artificial Intelligence Economy World Trade
ANGLE Announces Collaboration with Myriad Genetics
Via ACCESS Newswire
Myriad Genetics Appoints Ben Wheeler Chief Financial Officer
From Myriad Genetics, Inc.
Via GlobeNewswire
3 Healthcare Stocks We’re Skeptical Of
Personal health and wellness is one of the many secular tailwinds for healthcare companies. But speed bumps such as inventory destockings have persisted in the wake of COVID-19, and over the past six... 
Via StockStory
Topics Stocks
New Myriad Genetics Survey Uncovers Women Fear Screenings—But Feel Reassured by the Results
Cancer Risk Survey shows that more than half of women at high-risk for hereditary cancer would feel "empowered" by more advanced screening like genetic testing 
From Myriad Genetics, Inc.
Via GlobeNewswire
MYGN Q2 Deep Dive: Oncology Strategy Shift and Product Execution Shape Guidance
Genetic testing company Myriad Genetics (NASDAQ:MYGN) reported Q2 CY2025 results beating Wall Street’s revenue expectations, but sales were flat year on year at $213.1 million. The company’s full-year... 
Via StockStory
Topics Artificial Intelligence
What's going on in today's session
Looking for insights into the US markets one hour before the close of the markets on Wednesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. 
Via Chartmill
Why Is Myriad Genetics (MYGN) Stock Soaring Today
Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) jumped 36.4% in the afternoon session after the company reported strong second-quarter earnings that surpassed analyst expectations and... 
Via StockStory
Topics Artificial Intelligence
12 Health Care Stocks Moving In Wednesday's Intraday Session
 
Via Benzinga
Here are the top movers in Wednesday's session.
Stay up-to-date with the latest market trends in the middle of the day on Wednesday. Explore the top gainers and losers during today's session in our detailed report. 
Via Chartmill
Shopify, Astera Labs, Myriad Genetics, Grocery Outlet And Other Big Stocks Moving Higher On Wednesday
 
Via Benzinga
The market is filled with gapping stocks in Wednesday's session.
Traders are paying attention to the gapping stocks in Wednesday's session. Let's dive into which stocks are experiencing notable gaps. 
Via Chartmill
Discover the top movers in Wednesday's pre-market session.
The US market session of Wednesday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today. 
Via Chartmill
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
Stock Market Today: US Futures Edge Higher As Investors Await Earnings From McDonald's, Uber And Walt Disney
US stock futures rose on Wed. after falling on Thurs. Trump threatened tariffs on imported pharma up to 250%. Bond yields down & Fed may cut rates. 
Via Benzinga
Topics Economy Government World Trade
Why Astera Labs Shares Are Trading Higher By Over 17%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Myriad Genetics Surges 35.67% After Hours Following Strong Q2 Earnings Beat, Raised Revenue Guidance
After posting second-quarter results that beat revenue and EPS estimates and raising its 2025 guidance, Myriad Genetics jumped 35.66% to $5.25 after-hours on Tuesday. 
Via Benzinga
Topics Earnings
Myriad Genetics (MYGN) Q2 Revenue Up 6%
Via The Motley Fool
12 Health Care Stocks Moving In Tuesday's After-Market Session
 
Via Benzinga
Top movers in Tuesday's after hours session
Let's have a look at what is happening on the US markets after the closing bell on Tuesday. Below you can find the top gainers and losers in today's after hours session. 
Via Chartmill
Myriad Genetics (NASDAQ:MYGN) Reports Strong Q2, Stock Jumps 30.6%
Genetic testing company Myriad Genetics (NASDAQ:MYGN) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, but sales were flat year on year at $213.1 million. The company’s full-year... 
Via StockStory
Myriad Genetics Reports Second Quarter 2025 Financial Results; Raises 2025 Revenue Guidance Following Positive Business Momentum
From Myriad Genetics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.